An SLP company, DILIsym Services (DSS), is leading the development of RADAsym, a new quantitative systems pharmacology (QPS) platform.
Cognigen also will be working directly with the sponsor to curate data and support pharmacometric modeling activities.
The technology helps predict the effects of radiation in mice, non-human primates, and humans, in addition to the efficacy of interventions.
It will be used to help support approval for acute radiation syndrome (ARS) treatment under the Animal Rule, regulations which enable the approval of drugs and licensure of biological products in situations where human efficacy studies are not ethical or feasible.
The QPS platform will include major biological systems, including the vasculature and immune systems, the liver and GI tract, as well as the lung and bone marrow.
In the future, the RADAsym platform will be available for licensing and consulting services.
Said Shawn O’Connor, Simulations Plus CEO: "We are pleased to have been engaged by industry to support this critical development effort. Our expertise across QSP and PKPD techniques and model development positions us uniquely to satisfy the requirements of this endeavor. This engagement also demonstrates our ability to cross-sell the capabilities of our divisions.”